Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$46.68 USD
+1.06 (2.32%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $47.59 +0.91 (1.95%) 5:54 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Brokerage Reports
[RNA]
Reports for Purchase
Showing records 41 - 60 ( 62 total )
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 25
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Q3:13 Update -Waiting for Phase III Data Re-analysis- PRO053 Phase I/II Initiated
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Drisapersen and Phase III and Beyond -Encouraging Subset Analysis and Data from Follow-on Compounds- Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals/BioDefense - WMS Day 1 and KOL Dinner with Dr. McDonald and Friends - The Path Forward in DMD
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals/BioDefense - KOL Dinner with Dr. Craig McDonald, Oct 2 - Looking Ahead to World Muscle
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Key Takeaways - DIA/FDA Oligonucleotide-base Therapeutics Conference
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
DIA/FDA Oligonucleotide-base Therapeutics Conference
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
First Phase 3 Data Likely Oct 5 at WMS Meeting, Followed by Encore at OTS Oct 8 - Approval-Worthy Drisapersen Data Anticipated - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Q2:13 Update - Catalysts Ahead Beyond Phase III Data - Breakthrough Designation to Paves The Way to Approval in Our Opinion - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
Buy on Weakness - Positive Safety Data Showing Lower Incidence of Proteinuria Overlooked
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Aug. 12
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Research Grant to Accelerate Drisapersen Follow-on PRO045 Development
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C